Zoe Moodie

6.7k total citations · 1 hit paper
52 papers, 2.5k citations indexed

About

Zoe Moodie is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Zoe Moodie has authored 52 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Virology, 20 papers in Infectious Diseases and 16 papers in Epidemiology. Recurrent topics in Zoe Moodie's work include HIV Research and Treatment (30 papers), Immune Cell Function and Interaction (11 papers) and Mosquito-borne diseases and control (9 papers). Zoe Moodie is often cited by papers focused on HIV Research and Treatment (30 papers), Immune Cell Function and Interaction (11 papers) and Mosquito-borne diseases and control (9 papers). Zoe Moodie collaborates with scholars based in United States, South Africa and France. Zoe Moodie's co-authors include M. Juliana McElrath, Gary J. Nabel, Stephen C. De Rosa, Steven G. Self, Bimal K. Chakrabarti, Barney S. Graham, Zhi-Yong Yang, Wing-Pui Kong, John Hural and Mario Roederer and has published in prestigious journals such as The Lancet, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Zoe Moodie

49 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis

2008 517 citations M. Juliana McElrath, Stephen C. De Rosa et al. profile →

Peers

Countries citing papers authored by Zoe Moodie

Since Specialization

Citations

This map shows the geographic impact of Zoe Moodie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zoe Moodie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zoe Moodie more than expected).

Fields of papers citing papers by Zoe Moodie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zoe Moodie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zoe Moodie. The network helps show where Zoe Moodie may publish in the future.

Co-authorship network of co-authors of Zoe Moodie

This figure shows the co-authorship network connecting the top 25 collaborators of Zoe Moodie. A scholar is included among the top collaborators of Zoe Moodie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zoe Moodie. Zoe Moodie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deciphering HIV vaccine-induced antibody response according to ethnicity 2025 ·AIDS ·Li‐Yun Lin, (unknown), Mkunde Chachage, (unknown), Géraldine Laumond, Sylvie Schmidt, (unknown), Raphaël Carapito, Linda‐Gail Bekker, Gavin Churchyard, Michael C. Keefer, Zoe Moodie, (unknown), Christof Geldmacher, (unknown), Christiane Moog	0
2	Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies 2024 ·Cell Reports ·(unknown), Yu-Hsin Wan, Leah J. Homad, (unknown), (unknown), (unknown), Irika R. Sinha, (unknown), (unknown), (unknown), (unknown), A. Davis, Zoe Moodie, (unknown), Amelia Escolano, M. Juliana McElrath, Jim Boonyaratanakornkit, Marie Pancera, Andrew T. McGuire	3
3	Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702 2024 ·Vaccine ·(unknown), Jia Jin Kee, Zoe Moodie, Yunda Huang, Holly Janes, Sufia Dadabhai, Alison C. Roxby, Mary Allen, (unknown), (unknown), Craig Innes, Nivashnee Naicker, (unknown), Nicole Grunenberg, Mookho Malahleha, James G. Kublin, Linda‐Gail Bekker, Glenda Gray, Johnstone Kumwenda, Fatima Laher	1
4	Persistent serum protein signatures define an inflammatory subcategory of long COVID 2023 ·Nature Communications ·Aarthi Talla, Suhas Vasaikar, Gregory L. Szeto, Maria P. Lemos, Julie Czartoski, Hugh Macmillan, Zoe Moodie, Kristen W. Cohen, Lamar Ballweber-Fleming, Zachary Thomson, Lauren Okada, Lynne A. Becker, Ernest M. Coffey, Stephen C. De Rosa, Evan W. Newell, Peter J. Skene, Xiaojun Li, Thomas F. Bumol, M. Juliana McElrath, Troy R. Torgerson	70
5	mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RAint TEMRA-like CD8+ T cells in COVID-19 recovered individuals 2023 ·Cell Reports Medicine ·(unknown), Heeju Ryu, (unknown), K. Rachael Parks, (unknown), Kristen W. Cohen, Terri L. Stewart, Aaron Seese, Maria P. Lemos, Stephen C. De Rosa, Julie Czartoski, Zoe Moodie, Long Thành Nguyễn, Donald J. McGuire, Rafi Ahmed, Andrew Fioré-Gartland, M. Juliana McElrath, Evan W. Newell	7
6	Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia 2022 ·Vaccine ·Qi Li, Yanqing Sun, Michal Juraska, Zoe Moodie, Craig A. Magaret, (unknown), Lindsay N. Carpp, Peter B. Gilbert	1
7	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells 2019 ·Frontiers in Immunology ·Leigh H. Fisher, (unknown), Sherry Stanfield-Oakley, Lindsay N. Carpp, R. Whitney Edwards, Thomas N. Denny, Zoe Moodie, Fatima Laher, Linda‐Gail Bekker, M. Juliana McElrath, Peter B. Gilbert, Lawrence Corey, Georgia D. Tomaras, Justin Pollara, Guido Ferrari	23
8	Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease 2018 ·PLoS ONE ·Chloé Pasin, M. Elizabeth Halloran, Peter B. Gilbert, Edith Langevin, R. Leon Ochiai, Punnee Pitisuttithum, (unknown), Gabriel Carrasquilla, Carina Frago, Margarita Cortés, Laurent Chambonneau, Zoe Moodie	5
9	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men 2015 ·PLoS ONE ·Zoe Moodie, Barbara Metch, Linda‐Gail Bekker, Gavin Churchyard, Maphoshane Nchabeleng, Koleka Mlisana, Fatima Laher, Surita Roux, Kathryn Mngadi, Craig Innes, Matsontso Mathebula, Mary Allen, Carter Bentley, Peter B. Gilbert, Michael Robertson, James G. Kublin, Lawrence Corey, Glenda Gray	25
10	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study 2014 ·The Lancet Infectious Diseases ·Glenda Gray, Zoe Moodie, Barbara Metch, Peter B. Gilbert, Linda‐Gail Bekker, Gavin Churchyard, Maphoshane Nchabeleng, Koleka Mlisana, Fatima Laher, Surita Roux, Kathryn Mngadi, Craig Innes, Matsontso Mathebula, Mary Allen, (unknown), Michael Robertson, James G. Kublin, Lawrence Corey	82
11	New clinical trial designs for HIV vaccine evaluation 2013 ·Current Opinion in HIV and AIDS ·Zoe Moodie, Holly Janes, Yunda Huang	7
12	Comparing and combining data across multiple sources via integration of paired‐sample data to correct for measurement error 2012 ·Statistics in Medicine ·Yunda Huang, Ying Huang, Zoe Moodie, Sue Li, Steve Self	8
13	Comparison of Sexual Behavior and HIV Risk between Two HIV-1 Serodiscordant Couple Cohorts: The CHAVI 002 Study 2012 ·PLoS ONE ·Adam Ritchie, (unknown), Zoe Moodie, (unknown), Julie Fox, Rebecca N. Nsubuga, (unknown), (unknown), Pontiano Kaleebu, Andrew J. McMichael, Christine Watera, Nilu Goonetilleke, Sarah Fidler	4
14	Differences in HIV-Specific T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals 2011 ·Journal of Virology ·Adam Ritchie, Suzanne Campion, Jakub Kopycinski, Zoe Moodie, (unknown), K. Pandya, S. S. Moore, Michael K. P. Liu, Simon Brackenridge, (unknown), (unknown), Myron S. Cohen, Eric Delwart, Barton F. Haynes, Sarah Fidler, Andrew J. McMichael, Nilu Goonetilleke	33
15	Response Determination Criteria for ELISPOT: Toward a Standard that Can Be Applied Across Laboratories 2011 ·Methods in molecular biology ·Zoe Moodie, Leah Price, Sylvia Janetzki, Cedrik M. Britten	42
16	Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054) 2010 ·PLoS ONE ·Larry Peiperl, Cecilia Morgan, Zoe Moodie, Hongli Li, Nina D. Russell, Barney S. Graham, Georgia D. Tomaras, Stephen C. De Rosa, M. Juliana McElrath, (unknown)	38
17	Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination 2007 ·Journal of Immunological Methods ·Helen Horton, Evan P. Thomas, (unknown), Ian Frank, Zoe Moodie, Yunda Huang, Ya-Lin Chiu, M. Juliana McElrath, Stephen C. De Rosa	174
18	Statistical evaluation of HIV vaccines in early clinical trials 2006 ·Contemporary Clinical Trials ·Zoe Moodie, Anthony Rossini, Michael G. Hudgens, Peter B. Gilbert, Steven G. Self, Nina D. Russell	11
19	Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 DNA Candidate Vaccine 2006 ·The Journal of Infectious Diseases ·Barney S. Graham, Richard A. Koup, Mario Roederer, Robert T. Bailer, Mary E. Enama, Zoe Moodie, Julie E. Martin, (unknown), Bimal K. Chakrabarti, Laurie Lamoreaux, Charla Andrews, Phillip L. Gomez, John R. Mascola, Gary J. Nabel	151
20	Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials 2006 ·Journal of Immunological Methods ·Zoe Moodie, Yunda Huang, Lin Gu, John Hural, Steven G. Self	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact